Wiedmer Petra, Nogueiras Rubén, Broglio Fabio, D'Alessio David, Tschöp Matthias H
Department of Pharmacology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Nuthetal, Germany.
Nat Clin Pract Endocrinol Metab. 2007 Oct;3(10):705-12. doi: 10.1038/ncpendmet0625.
The high prevalence of obesity and diabetes will lead to higher rates of morbidity and mortality. The search for drugs to treat these metabolic disorders has, therefore, intensified. The stomach-derived peptide ghrelin regulates food intake and body weight. Recent work suggests that ghrelin also controls glucose metabolism. In addition, current evidence suggests that most of the actions of ghrelin could contribute to the metabolic syndrome. The ghrelin signaling system is, therefore, a promising target for the development of new drugs for the treatment of obesity and diabetes. Agents that block the ghrelin signaling system might be especially useful targets. This Review summarizes the potential and the limitations of ghrelin as a tool to better understand, prevent and treat obesity and diabetes.
肥胖症和糖尿病的高患病率将导致更高的发病率和死亡率。因此，寻找治疗这些代谢紊乱疾病的药物的研究力度加大。胃源性肽胃饥饿素调节食物摄入和体重。最近的研究表明，胃饥饿素还控制葡萄糖代谢。此外，目前的证据表明，胃饥饿素的大多数作用可能与代谢综合征有关。因此，胃饥饿素信号系统是开发治疗肥胖症和糖尿病新药的一个有前景的靶点。阻断胃饥饿素信号系统的药物可能是特别有用的靶点。本综述总结了胃饥饿素作为更好地理解、预防和治疗肥胖症及糖尿病的工具的潜力和局限性。
